kidney disease

Showing 15 posts of 15 posts found.

Takeda presents positive results from trial of chronic kidney disease treatment

June 10, 2025
Research and Development European Renal Association, Immunology, Nephrology, Takeda, autoimmune disease, immunoglobulin A nephropathy (IgAN), kidney disease

Takeda Pharmaceuticals has announced positive results from a proof-of-concept study of mezagitamab (TAK-079) to treat patients with primary immunoglobulin A …

NICE recommends treatment for chronic kidney disease, IgA nephropathy

May 23, 2025
Market & Product Development, Medical Communications, Research and Development IgA nephropathy, National Institute for Health and Care Excellence, Nephrology, kidney disease

The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Viforโ€™s FILSPARI (sparsentan) for …

europe-1395916_640

EU approval granted for rare kidney disease treatment

April 29, 2025
Market Access, Research and Development, Sales and Marketing CSL Vifor, EU, Nephrology, Travere Therapeutics, kidney disease, nephrology

The EU has granted marketing authorisation (MA) for Filspari โ€“ CSL Vifor and Travere Therapeuticsโ€™ therapy for primary IgA nephropathy …

Renalys Pharma closes ยฅ6bn series A financing for kidney disease treatments in Asia

July 17, 2024
Business Services Financing, Nephrology, kidney disease, renalys Pharma

Renalys Pharma has announced that it has completed ยฅ6bn series A financing, which was led by Catalys Pacific and SR …

AstraZeneca shares results from ZENITH-CKD phase 2b trial for chronic kidney disease and proteinuria treatment

November 6, 2023
Research and Development AstraZeneca, CKD, Nephrology, kidney disease, proteinuria

AstraZeneca has announced results from the ZENITH-CKD phase 2b clinical trial for the combination of zibotentan with dapagliflozin for the …

kidney

Novartis acquires Chinook Therapeutics for $3.5bn

June 12, 2023
Mergers and Acquisitions Chinook Therapeutics, Nephrology, Novartis, kidney disease, pharma

Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based biopharmaceutical company Chinook Therapeutics for …

AstraZeneca drug approved by FDA for kidney disease treatment

May 4, 2021
Manufacturing and Production AstraZeneca, FDA, kidney disease, pharma, pharma news

AstraZenecaโ€™s Farxiga drug has been approved for the treatment of chronic kidney disease (CKD) in the US by the FDA.

Evotec building

Evotec and Chinook to partner on new kidney disease treatments

March 1, 2021
Sales and Marketing CKD, Chinook, Evotec, chronic kidney disease, kidney disease

Evotec and Chinook Therapeutics have agreed a deal to discover and develop new therapies for patients with chronic kidney diseases …

190509-f-jf989-059

NICE does not recommend cancer drug combination to the NHS

February 13, 2020
Business Services Cancer, Kidney cancer, NHS, NICE, keytruda, kidney disease

NICE has published draft guidance that does not recommend a new drug combination to combat untreated advanced renal cell carcinoma …

baxter

Baxter partners up with Mayo Clinic for new “centre of exellence” in renal care

October 4, 2018
Research and Development Mayo Clinic, baxter, kidney disease, pharma, renal

American pharma firm Baxter has announced a new partnership with the Mayo Clinic in a bid to establish a โ€œrenal …

jj_sign_on_wall

J&J stops Invokana trial early after success in kidney disease and type 2 diabetes

July 17, 2018
Manufacturing and Production, Research and Development J&J, JJ, Janssen, Johnson & Johnson, invokana, kidney disease, pharma, renal, type 2 diabetesm diabetes

Johnson & Johnson and research arm Janssen have taken the decision to terminate a Phase 3 trial evaluating the efficacy …

Jinarc

SMC approves first ever treatment for genetic kidney disease

January 12, 2016
Sales and Marketing Otsuka, SMC, Scottish Medicines Consortium, jinarc, kidney disease, tolvaptan

The Scottish Medicines Consortium (SMC) has approved Otsukaโ€™s Jinarc for the treatment of the genetic kidney disease autosomal dominant polycystic …

Jinarc

Otsuka kidney drug earns first NICE nod

October 28, 2015
Research and Development, Sales and Marketing NHS, NICE, jinarc, kidney disease, tolvaptan

NICE has released final guidance recommending Otsukaโ€™s Jinarc, the first-ever treatment shown to slow progression of life-threatening Autosomal Dominant Polycystic …

The Gateway to Local Adoption Series

Latest content